{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.45","upperLimit":"0.86","value":"0.71"},{"groupId":"OG001","lowerLimit":"0.31","upperLimit":"0.72","value":"0.54"},{"groupId":"OG002","lowerLimit":"0.45","upperLimit":"0.75","value":"0.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"The probability was estimated from the K-M curve of subjects being alive and without disease progression (modified IMWG criteria) at 2 years from the initiation of study therapy by dose cohort","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants in 2 arms were enrolled sequentially. The first group of participants received elotuzumab intravenously at a dose of 20 mg/kg on Days 1 and 8 per 28-day cycle for Cycle 1 and then on Day 1 only in subsequent cycles.","id":"OG000","title":"Elotuzumab, 20 mg/kg"},{"description":"Participants in the second group received elotuzumab intravenously at a dose of 10 mg/kg weekly per 28-day cycle in Cycles 1 and 2, then on Days 1 and 15 in subsequent cycles.","id":"OG001","title":"Elotuzumab, 10 mg/kg"},{"description":"All participants on Elotuzumab therapy. Comprised of both the 20mg/kg and 10mg/kg arms","id":"OG002","title":"Elotuzumab, All Dosages"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Up to 2 years from the initiation of study therapy by dose cohort (approximately 24 months)","title":"Progression Free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"Probability of Progression Free Survival"}